<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04952545</url>
  </required_header>
  <id_info>
    <org_study_id>ALXN2050-HV-113</org_study_id>
    <nct_id>NCT04952545</nct_id>
  </id_info>
  <brief_title>Study of ALXN2050 in Healthy Adult Participants of Japanese Descent</brief_title>
  <official_title>A Phase 1 Study to Determine the Safety, Tolerability, and Pharmacokinetics of ALXN2050 in Healthy Participants of Japanese Descent</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexion Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexion Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 bridging study being conducted to evaluate the safety, tolerability,&#xD;
      pharmacokinetics, and pharmacodynamics of ALXN2050 after both single- and multiple-dosing in&#xD;
      healthy participants of Japanese descent.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number Of Participants With Treatment-emergent Adverse Events</measure>
    <time_frame>Day 1 (after first dose) through follow-up (7 +/- 2 days after final dose)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under The Concentration-time Curve From Time Zero To Infinity (AUCinf) For Single-dose ALXN2050</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) For Single-dose ALXN2050</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time To Maximum Plasma Concentration (Tmax) For Single-dose ALXN2050</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under The Concentration-time Curve From Time Zero To The 12-hour Time Point (AUC0-12) For Multiple-dose ALXN2050</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax For Multiple-dose ALXN2050</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax For Multiple-dose ALXN2050</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Alternative Pathway Activity As Measured By Wieslab Assay</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complement Factor B Fraction b Levels</measure>
    <time_frame>Up to 72 hours postdose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1: ALXN2050 (Dose 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ALXN2050 (Dose 1) as follows under fasting conditions: 120-milligrams (mg) single dose, 3-day washout, then 120-mg twice daily (BID) dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1: Placebo (Dose 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive placebo (Dose 1) as follows under fasting conditions: 120-mg placebo single dose, 3-day washout, then 120-mg placebo BID dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: ALXN2050 (Dose 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive ALXN2050 (Dose 2) as follows under fasting conditions: 180-mg single dose, 3-day washout, then 180-mg BID dosing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2: Placebo (Dose 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive placebo (Dose 2) as follows under fasting conditions: 180-mg placebo single dose, 3-day washout, then 180-mg placebo BID dosing.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALXN2050</intervention_name>
    <description>Oral tablet.</description>
    <arm_group_label>Cohort 1: ALXN2050 (Dose 1)</arm_group_label>
    <arm_group_label>Cohort 2: ALXN2050 (Dose 2)</arm_group_label>
    <other_name>ACH-0145228 (formerly)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablet.</description>
    <arm_group_label>Cohort 1: Placebo (Dose 1)</arm_group_label>
    <arm_group_label>Cohort 2: Placebo (Dose 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Medically healthy with no clinically significant or relevant abnormalities as&#xD;
             determined by medical history, physical or neurological examination, vital signs,&#xD;
             12-lead electrocardiogram, screening clinical laboratory profiles.&#xD;
&#xD;
          -  Participants must be of Japanese descent defined as:&#xD;
&#xD;
               -  First generation (born to 2 Japanese parents and 4 Japanese grandparents);&#xD;
&#xD;
               -  Born in Japan, and not have lived outside Japan for greater than 5 years;&#xD;
&#xD;
               -  Lifestyle, including diet, must not have significantly changed since leaving&#xD;
                  Japan.&#xD;
&#xD;
          -  Participants must be able to speak, read, and understand the Japanese and English&#xD;
             languages.&#xD;
&#xD;
          -  Body mass index within the range 18.5 to 30.0 kilograms (kg)/meter squared, inclusive,&#xD;
             with a minimum body weight of 50.0 kg at Screening.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History of any medical or psychiatric condition or disease that, in the opinion of the&#xD;
             Investigator or designee, might limit the participant's ability to complete or&#xD;
             participate in this clinical study, confound the results of the study, or pose an&#xD;
             additional risk to the participant by their participation in the study.&#xD;
&#xD;
          -  History of significant multiple and/or severe allergies.&#xD;
&#xD;
          -  Any previous procedure that could alter absorption or excretion of orally administered&#xD;
             drugs.&#xD;
&#xD;
          -  Participation in another investigational drug or investigational device study within 5&#xD;
             half-lives (if known) or 30 days prior to the first dose of study intervention,&#xD;
             whichever is longer.&#xD;
&#xD;
          -  Body temperature ≥ 38.0°Celcius, at Screening or prior to the first dose of study&#xD;
             intervention.&#xD;
&#xD;
          -  History of drug or alcohol abuse within 2 years prior to the first dose of study&#xD;
             intervention or positive drugs-of-abuse or alcohol screen at Screening or Day -1;&#xD;
             current tobacco/nicotine users or smokers or a positive cotinine test at Screening.&#xD;
&#xD;
          -  Donation of whole blood from 3 months prior to the first dose of study intervention,&#xD;
             or of plasma from 30 days prior to the first dose of study intervention; receipt of&#xD;
             blood products within 6 months prior to the first dose of study intervention.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Alexion Pharmaceuticals, Inc.</last_name>
    <phone>1-855-752-2356</phone>
    <email>clinicaltrials@alexion.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Clinical Trial Site</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 28, 2021</study_first_submitted>
  <study_first_submitted_qc>June 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2021</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALXN2050</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Japanese Descent</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

